L-type amino-acid transporter 1 expression predicts the response to preoperative hyperthermo-chemoradiotherapy for advanced rectal cancer
- PMID: 21036745
L-type amino-acid transporter 1 expression predicts the response to preoperative hyperthermo-chemoradiotherapy for advanced rectal cancer
Abstract
Aim: To evaluate whether expression of L-type amino acid transporter 1 (LAT1) in pretreatment rectal cancer biopsies is predictive of tumour response to neoadjuvant hyperthermo-chemoradiotherapy (HCRT).
Patients and methods: Forty-four patients with rectal adenocarcinoma who received neoadjuvant HCRT were investigated. LAT1 expression was immunohistochemically evaluated using pretreatment biopsies. The operation was performed after 2-3 months following HCRT and each resected specimen was graded by the histological criteria of the Japanese Classification of Colorectal Carcinoma.
Results: A positive LAT1 expression was recognized in 50.0% (22/44) of patients. Resected specimens were divided into 2 groups according to the histological grading criteria: good response (n=29) and poor response (n=15). LAT1-negative tumours had an 81.8% probability of good response and 18.2% probability of poor response. LAT1 expression showed marginally significant association with response to HCRT (p=0.05).
Conclusion: LAT1 may be a useful predictive marker of response to HCRT in rectal cancer.
Similar articles
-
The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.Colorectal Dis. 2012 May;14(5):555-61. doi: 10.1111/j.1463-1318.2011.02697.x. Colorectal Dis. 2012. PMID: 21689364
-
Effect of long interval between hyperthermochemoradiation therapy and surgery for rectal cancer on apoptosis, proliferation and tumor response.Anticancer Res. 2014 Jun;34(6):3141-6. Anticancer Res. 2014. PMID: 24922685
-
Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.Clin Oncol (R Coll Radiol). 2010 May;22(4):272-80. doi: 10.1016/j.clon.2010.01.001. Epub 2010 Feb 1. Clin Oncol (R Coll Radiol). 2010. PMID: 20117921
-
[Histologic response after neoadjuvant therapy in rectal adenocarcinoma: own experience and review of the literature].Orv Hetil. 2006 Oct 22;147(42):2011-20. Orv Hetil. 2006. PMID: 17165600 Review. Hungarian.
-
Tailoring treatment of rectal adenocarcinoma: immunohistochemistry for predictive biomarkers.Anticancer Drugs. 2011 Apr;22(4):362-70. doi: 10.1097/CAD.0b013e3283433764. Anticancer Drugs. 2011. PMID: 21233707 Review.
Cited by
-
The role of LAT1 in (18)F-DOPA uptake in malignant gliomas.J Neurooncol. 2013 Jan;111(1):11-8. doi: 10.1007/s11060-012-0986-1. Epub 2012 Oct 20. J Neurooncol. 2013. PMID: 23086431 Free PMC article.
-
Chemoradiotherapy and concurrent radiofrequency thermal therapy to treat primary rectal cancer and prediction of treatment responses.Oncol Rep. 2017 Feb;37(2):695-704. doi: 10.3892/or.2016.5300. Epub 2016 Dec 7. Oncol Rep. 2017. PMID: 27959450 Free PMC article.
-
Contribution of LAT1-4F2hc in Urological Cancers via Toll-like Receptor and Other Vital Pathways.Cancers (Basel). 2022 Jan 4;14(1):229. doi: 10.3390/cancers14010229. Cancers (Basel). 2022. PMID: 35008399 Free PMC article. Review.
-
LAT-1 activity of meta-substituted phenylalanine and tyrosine analogs.Bioorg Med Chem Lett. 2016 Jun 1;26(11):2616-2621. doi: 10.1016/j.bmcl.2016.04.023. Epub 2016 Apr 11. Bioorg Med Chem Lett. 2016. PMID: 27106710 Free PMC article.
-
l-Type amino acid transporter 1 activity of 1,2,3-triazolyl analogs of l-histidine and l-tryptophan.Bioorg Med Chem Lett. 2019 Aug 15;29(16):2254-2258. doi: 10.1016/j.bmcl.2019.06.033. Epub 2019 Jun 20. Bioorg Med Chem Lett. 2019. PMID: 31248771 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
